BrainsWay - ADR Peer Comparison

$14.30

$-0.10 (-0.69%)

As on 28-Aug-2026 16:00EDT

Market cap

$575 Mln

Revenue (TTM)

$61 Mln

P/E Ratio

62.2

P/B Ratio

7.3

Div. Yield

0 %

Edit

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	575	12,753	10,906	9,948	9,762
Revenue ($ Mln)	61	1,505	613	785	2,589
Net Profit ($ Mln)	9.55	160.59	-188.05	41.54	222.40
Net Margin (%)	15.65	10.67	-30.68	5.29	8.59
RoE (%)	12.53	10.86	-28.10	1.97	3.04
Price to Earnings	62.17	79.35	--	251.81	44.47
Price-To-Book	7.31	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	60.99	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	15.05	483.98	127.96	384.30	1,245.50
Gross Profit	39.39	942.44	393.22	347.62	1,343.60
Operating Expenses	38.33	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	7.61	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	9.73	203.83	-192.83	52.15	350.40
Provision for Tax	0.18	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	9.55	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	79.19	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	15.72	210.18	135.71	705.49	2,116.80
Current Liabilities	22.67	233.78	102.33	132.66	961.30
Total Liabilities	112.92	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	40.55	630.60	404.74	1,749.63	7,231.50
Current Assets	81.42	1,344.12	515.78	1,200.55	3,020.50
Total Assets	112.92	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	7.13	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	18.16	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-17.63	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-2.23	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	10.32	11.76	-22.53	1.79	8.98
ROE (%)	12.53	10.86	-28.10	1.97	3.04
ROA (%)	5.61	7.95	-18.00	1.36	2.02
EBIT Margin (%)	17.24	13.63	-30.58	9.87	-5.99
Net Margin (%)	15.65	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	32.34	17.55	41.55	16.49	1.37
EBIT Growth (%)	67.58	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	78.62	8.72	-102.66	400.42	-30.32
EPS Growth (%)	205.62	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	118.90	17.33	-12.65	2.16	2.19

Valuation Ratios

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	52.23	68.93	-34.59	189.42	--
Price / Book Value	7.31	8.58	9.90	4.86	--
Dividend Yield (%)	0.00	--	--	0.00	--
EV/EBITDA	42.06	53.25	-43.50	81.02	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.02	0.01	0.00	0.01	0.06
Current Ratio	3.59	5.75	5.04	9.05	3.14
Quick Ratio	3.27	3.86	4.46	7.64	2.33
Interest Coverage	5.39	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	BrainsWay - ADR	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	11.53	12.65	22.67	20.09	17.06
Asset Turnover	0.36	0.74	0.59	0.26	0.24
Receivable days	30.45	46.54	60.95	72.41	65.39
Inventory Days	164.43	331.92	193.84	146.53	221.09
Payable days	75.33	26.16	60.19	29.05	37.02
Cash Conversion Cycle	119.55	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly